Literature DB >> 19482614

Mechanisms underlying morphine analgesic tolerance and dependence.

Hiroshi Ueda1, Mutsumi Ueda.   

Abstract

The mechanisms underlying opioid tolerance are not fully understood, but appear to be comprised of two types of plasticity or counter-adaptation, at the cellular level and through neuronal circuits. Current studies mostly emphasize the cellular adaptation mechanisms, which include altered gene expression and receptor desensitization due to phosphorylation and endocytosis. However, the mechanisms underlying opioid tolerance and dependence are not always explained by cellular adaptation mechanisms alone. This review focuses on the plasticity in neuronal circuits achieved through an enhancement of synaptic activities between glutamate and NMDA receptor due to up-regulation of receptor and racemase to produce D-serine, an allosteric NMDA receptor agonist, and down-regulation of glutamate transporter, all which contribute to the counterbalance of opioid actions or anti-opioid mechanisms underlying opioid tolerance. This anti-opioid system is supposed to be also augmented by altered expression of key molecules regulating through neuron-glial networks. This review also introduces a new approach using in vivo electroporation to identify the brain loci responsible for morphine tolerance and dependence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19482614     DOI: 10.2741/3596

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  35 in total

1.  Chronic methadone treatment shows a better cost/benefit ratio than chronic morphine in mice.

Authors:  Johan Enquist; Madeline Ferwerda; Laura Milan-Lobo; Jennifer L Whistler
Journal:  J Pharmacol Exp Ther       Date:  2011-11-07       Impact factor: 4.030

2.  Morphine and MK-801 administration leads to alternative N-methyl-D-aspartate receptor 1 splicing and associated changes in reward seeking behavior and nociception on an operant orofacial assay.

Authors:  E M Anderson; A Y Del Valle-Pinero; S K Suckow; T A Nolan; J K Neubert; R M Caudle
Journal:  Neuroscience       Date:  2012-04-21       Impact factor: 3.590

Review 3.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

Review 4.  The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia.

Authors:  Linda R Watkins; Mark R Hutchinson; Kenner C Rice; Steven F Maier
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

5.  PolyMorphine: an innovative biodegradable polymer drug for extended pain relief.

Authors:  Roselin Rosario-Meléndez; Carolyn L Harris; Roberto Delgado-Rivera; Lei Yu; Kathryn E Uhrich
Journal:  J Control Release       Date:  2012-08-03       Impact factor: 9.776

Review 6.  Adverse effects of chronic opioid therapy for chronic musculoskeletal pain.

Authors:  Leslie J Crofford
Journal:  Nat Rev Rheumatol       Date:  2010-04       Impact factor: 20.543

Review 7.  [Sedation and analgesia in intensive care: physiology and application].

Authors:  David M Baron; Philipp G H Metnitz; Burkhard Gustorff
Journal:  Wien Klin Wochenschr       Date:  2010-08       Impact factor: 1.704

Review 8.  Non-coding RNAs--novel targets in neurotoxicity.

Authors:  Tamara L Tal; Robert L Tanguay
Journal:  Neurotoxicology       Date:  2012-02-27       Impact factor: 4.294

Review 9.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

10.  Co-activation of μ- and δ-opioid receptors elicits tolerance to morphine-induced ventilatory depression via generation of peroxynitrite.

Authors:  Alex P Young; Ryan B Gruber; Joe F Discala; Walter J May; Dylan McLaughlin; Lisa A Palmer; Stephen J Lewis
Journal:  Respir Physiol Neurobiol       Date:  2013-03-05       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.